Unexpected skin lesions secondary to metastasis of urothelial carcinoma.
Metastasis
Neoplasms
Skin metastasis
Urothelial bladder carcinoma
Journal
International journal of surgery case reports
ISSN: 2210-2612
Titre abrégé: Int J Surg Case Rep
Pays: Netherlands
ID NLM: 101529872
Informations de publication
Date de publication:
2019
2019
Historique:
received:
01
10
2019
accepted:
05
10
2019
pubmed:
2
11
2019
medline:
2
11
2019
entrez:
1
11
2019
Statut:
ppublish
Résumé
Metastatic spread of urothelial bladder carcinoma (UBC) rarely involves the skin which is associated with a poor prognosis. We present a rare case of UBC with cutaneous metastases which is exceptional by its inflammatory clinical form. A 62-year-old male was diagnosed with a non-metastatic muscle invasive transitional cell bladder carcinoma invading the anterior wall of the rectum. Cisplatin-based chemotherapy was indicated but refused by the patient. Three months later, he developed cutaneous lesions in the left axilla and the right inguinal fold. These lesions were budding, nodular and inflammatory corresponding to carcinomatous metastasis on skin biopsy which urothelial origin was confirmed by immunohistochemical analysis. The patient died four weeks later after multi-organ failure. Skin metastasis of transitional cell carcinoma of the bladder are uncommon, representing 0.84% of all cutaneous metastases. The inflammatory presentation, as seen in our case, is rarer than the other types and is usually due to a lymphatic extension. The clinical appearance of cutaneous metastases might mimic other common dermatologic disorders; Thus, diagnosis requires histological confirmation by microscopic examination and immunohistochemical study of a skin biopsy. The prognosis after the appearance of cutaneous metastases is generally poor with a median disease-specific survival of less than 12 months Treatment is palliative and is principally based on chemotherapy, analgesics and psychological support. Cutaneous metastases secondary to urothelial bladder carcinoma are exceptional especially in its inflammatory presentation. Diagnosis is based on immunohistochemical study. Treatment is based on chemotherapy and the prognosis is poor.
Identifiants
pubmed: 31670145
pii: S2210-2612(19)30553-X
doi: 10.1016/j.ijscr.2019.10.007
pmc: PMC6831817
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
177-179Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
Arch Dermatol. 1968 Jun;97(6):678-84
pubmed: 4297449
Urology. 2004 Jun;63(6):1021-6
pubmed: 15183939
Int J Surg. 2018 Dec;60:132-136
pubmed: 30342279
Arch Dermatol. 1973 Jan;107(1):80-6
pubmed: 4682547
J Cytol. 2014 Jan;31(1):50-2
pubmed: 25190986
Urology. 2006 Apr;67(4):846.e15-7
pubmed: 16600346
Chang Gung Med J. 2003 Jul;26(7):525-9
pubmed: 14515977